Anomalous protein-protein interactions (PPIs) have been correlated to a variety of disease
states, such as cancer, infectious disease, neurological disorders, diabetes, endocrine disorders and cardiovascular
disease. Stapled peptides are an emerging intervention for these PPIs due to their improved
structural rigidity and pharmacokinetic properties relative to unstapled peptides. This review details the
most recent advances in the field of stapled peptide therapeutics, including the increasing variety of PPIs
being targeted and types of peptide staples being employed.